The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Detailed price information for Mainz Biomed N.V. (MYNZ-Q) from The Globe and Mail including charting and trades.

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid ...

aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat ...

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...

Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead candidate.

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ...

The use of B-cell–depleting antibodies for autoimmune disease has been well validated with significant use of Roche Holdings AG (OTC:RHHBY) and Biogen Inc (NASDAQ:BIIB) partnered Rituxan (rituximab) ...

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches are starting to deliver meaningful revenue. The sector is turning profitable ...